Why so few Lyme cases in South & West?

Why Doesn't CDC Count Lyme Disease Cases in South and West? Everybody Else Does. CDC surveillance maps show Lyme exposure as primarily an East Coast phenomenon. But a look at data from other sources offers an entirely different picture. More from LYME POLICY WONK.  More from our news blogs LYME SCI: The dreaded Jarisch-Herxheimer reaction Cracking the code of chronic fatigue syndrome Lyme disease's worst enemy? It might be foxes. Nominations for Tick-borne Disease Working Group  Latest digital Lyme Times: "Lyme Brain" and more LymeDisease.org, publisher of The Lyme Times, is the Lyme community's leading source of news, information, and health policy analysis.  Become a member today.

Is the Medical Community Behind the Times When It Comes to Treating Lyme?

Is the Medical Community Behind the Times When It Comes to Treating Lyme?

Lyme Disease Association President, Pat Smith, takes on the major problems surrounding Lyme disease today.

http://www.contagionlive.com/news/is-the-medical-community-behind-the-times-when-it-comes-to-treating-lyme?p=1

 

The effect of artesunate on short-term memory in Lyme borreliosis. - PubMed - NCBI

https://www.ncbi.nlm.nih.gov/pubmed/?term=The+effect+of+artesunate+on+short-term+memory+in+Lyme+borreliosis.

Med Hypotheses. 2017 Aug;105:4-5. doi: 10.1016/j.mehy.2017.06.015. Epub 2017 Jun 24.
The effect of artesunate on short-term memory in Lyme borreliosis.

Puri BK1, Hakkarainen-Smith JS2, Monro JA3.


Abstract

Lyme borreliosis is associated with memory deficits. While this may be related to cerebral infection by Borrelia bacteria, it may also be caused by concomitant co-infection by Babesia protozoa. The anti-malarial artemisinin-derivative artesunate has been shown to be effective against a number of Babesia species and to have efficacy against human cerebral malaria. We hypothesised that concomitant administration of artesunate in Lyme borreliosis patients would help alleviate the severity of self-reported short-term memory impairment. This hypothesis was tested in a small pilot study in which patients were treated with both an intravenous antibiotic and oral artesunate (20mg four times per day); treatment was associated with a reduction in the severity of short-term memory difficulties (P≃0.08). In light of these findings, we recommend that a formal randomised, placebo-controlled study be carried out.

Copyright © 2017 Elsevier Ltd. All rights reserved.

PMID:
   28735651
DOI:
   10.1016/j.mehy.2017.06.015